Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

European approvals face delay from agency move

October 25, 2017, EP Vantage

Grant Castle is quoted in an EP Vantage article examining how the move of the European Medicines Agency from London will impact European drug approvals. According to Castle, the main consequence of lower staff numbers could be longer waiting times to file drugs. “Because of the regulatory timetable there isn’t a huge amount of scope for delaying reviews, but companies could find it difficult to get their drugs into the queue for filing." 

Castle adds that if the EMA moves east salary levels, which are based on average wages in the host country, could be significantly reduced. “That’s why London is popular, because the EMA can pay the salaries that sophisticated high-tech employees expect. If it moves to Sofia the salary levels might not be enough to attract the highly skilled people it needs.” He also believes that demands from the east could indeed influence the eventual destination of the agency. “If you had a significant number of newer member states pressing for a EU institution in their territory it would have some political weight,” he says. If an Eastern European city is selected, this might not be the end of the world, Castle adds.

 

Share this article: